Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

X4 Pharmaceuticals (XFOR) Income from Continuing Operations (2018 - 2025)

X4 Pharmaceuticals' Income from Continuing Operations history spans 8 years, with the latest figure at 23925000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations rose 39.92% year-over-year to 23925000.0; the TTM value through Dec 2025 reached 79199000.0, down 111.48%, while the annual FY2025 figure was 79199000.0, 111.48% down from the prior year.
  • Income from Continuing Operations reached 23925000.0 in Q4 2025 per XFOR's latest filing, up from 29815000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 90833000.0 in Q2 2024 to a low of 55712000.0 in Q2 2023.
  • Average Income from Continuing Operations over 5 years is 20018950.0, with a median of 22945000.0 recorded in 2022.
  • The largest YoY upside for Income from Continuing Operations was 263.04% in 2024 against a maximum downside of 1492.02% in 2024.
  • A 5-year view of Income from Continuing Operations shows it stood at 30207000.0 in 2021, then increased by 3.65% to 29104000.0 in 2022, then skyrocketed by 34.27% to 19130000.0 in 2023, then crashed by 108.16% to 39821000.0 in 2024, then skyrocketed by 39.92% to 23925000.0 in 2025.
  • Per Business Quant, the three most recent readings for XFOR's Income from Continuing Operations are 23925000.0 (Q4 2025), 29815000.0 (Q3 2025), and 25741000.0 (Q2 2025).